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Background: The aim of this study was to evaluate the effect of levosimendan on mortality 
in cardiogenic shock (CS) after ST elevation myocardial infarction (STEMI).
Methods and results: Data were obtained prospectively from the SCAAR (Swedish Coro-
nary Angiography and Angioplasty Register) and the RIKS-HIA (Register of Information and 
Knowledge about Swedish Heart Intensive Care Admissions) about 94 consecutive patients with 
CS due to STEMI. Patients were classified into levosimendan-mandatory and levosimendan-
contraindicated cohorts. Inotropic support with levosimendan was mandatory in all patients 
between January 2004 and December 2005 (n = 46). After the SURVIVE and REVIVE II studies 
were presented, levosimendan was considered contraindicated and was not used in consecutive 
patients between December 2005 and December 2006 (n = 48). The cohorts were similar with 
respect to pre-treatment characteristics and concomitant medications. There was no difference in 
the incidence of new-onset atrial fibrillation, in-hospital cardiac arrest and length of stay at the 
coronary care unit. There was no difference in adjusted mortality at 30 days and at one year.
Conclusion: The use of levosimendan neither improves nor worsens mortality in patients with 
CS due to STEMI. Well-designed randomized clinical trials are needed to define the role of 
inotropic therapy in the treatment of CS.
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Introduction
Cardiogenic shock (CS) complicates 7%–10% of acute myocardial infarctions (MI) 
and is the leading cause of death in patients hospitalized for MI, with mortality rates 
of up to 60%.1–3 There is a scarcity of scientific data defining the role of inotropic and 
other therapy in the treatment of CS. Levosimendan is a novel inotropic drug with 
vasodilator effects that is used in the treatment of CS.4 In 2003, Sweden was one of 
the first countries to approve levosimendan (Simdax®) for an indication in acute heart 
failure (AHF). Since then, this agent has been increasingly used in Swedish hospitals, 
not only for AHF but also for “off-label” indications5,6 including treatment of CS,7 
despite that levosimendan’s efficacy and safety in these patients has not been prop-
erly assessed. Two randomized clinical trials have recently demonstrated no survival 
benefit for levosimendan over dobutamine8 (SURVIVE) or placebo9–13 (REVIVE II) 
in patients with AHF. On the contrary, the results have created the legitimate concern 
as to whether levosimendan might actually increase mortality, because increased 
incidences of hypotension and malignant ventricular arrhythmia, and more deaths 
were reported in REVIVE II with levosimendan compared with placebo.11–13 Because 
patients with CS are particularly sensitive to arrhythmias and worsening hypotension, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
658
Omerovic et al
it is essential to gather all available information about the 
effects of this drug in CS. Therefore, the aim of this study 
was to evaluate the effects of levosimendan on short-term 
and long-term mortality rates in CS.
Patients and methods
Patient characteristics
All consecutive patients presenting with CS due to ST 
elevation myocardial infarction (STEMI) between January 
2004 and December 2006 were enrolled in this registry 
study. Shock was defined by the SHOCK trial criteria14 
as follows: presence of hypotension (a systolic blood 
pressure of ,90 mmHg for at least 30 minutes or the 
need for supportive measures to maintain a systolic blood 
pressure of .90 mmHg) and end-organ hypoperfusion (cool 
extremities or a urine output of ,30 mL per hour, and a heart 
rate of .60 beats per minute). Data were obtained from the 
SCAAR15 (Swedish Coronary Angiography and Angioplasty 
Register) and RIKS-HIA16 (Register of Information and 
Knowledge about Swedish Heart Intensive Care Admissions) 
registries and from patient charts. The SCAAR and RIKS-
HIA registries contain detailed data (patient’s characteristics, 
treatment data, outcome, etc.) on consecutive patients from 
all hospitals that perform coronary interventions and pro-
vide intensive coronary care in Sweden. The registries are 
sponsored by the Swedish Health Authorities. The technol-
ogy is developed and administered by the Uppsala Clinical 
Research Center. Since 2001, SCAAR and RIKS-HIA have 
been Internet-based with data recorded online through a 
Web interface. For the purpose of this study, we extracted 
and analyzed data reported only from our hospital, ie, Sahlg-
renska University Hospital (SU). The SU is situated in Goth-
enburg and is the largest hospital in Scandinavia, providing 
specialized health care for ∼1.5 million inhabitants in the 
Västra Götaland region of western Sweden. There are seven 
additional primary hospitals in this region. The treatment 
strategy for CS at Västra Götaland is based on the Euro-
pean Society of Cardiology (ESC)/American Heart Asso-
ciation (AHA)/American College of Cardiology (ACC)17,18 
recommendations. The most important priority in the health 
care chain for CS patients is to provide expeditious primary 
percutaneous coronary intervention (PCI) with around-the-
clock availability. Ninety-four consecutive patients who 
fulfilled the inclusion criteria were enrolled between January 
2004 and December 2006. The patients were transported 
for acute angiography and PCI from the Gothenburg area 
(n = 47) as well as from areas covered by the 7 primary 
hospitals in Västra Götaland (n = 47) according to the local 
regional guidelines. A successful angioplasty was defined 
as following: no more than 50% post-intervention stenosis, 
an improvement of at least 20% in the degree of stenosis, 
and a flow of thrombolysis in myocardial infarction (TIMI) 
grade II or III.14 The completeness of revascularization was 
defined as following: no more than 10% of the left ventricular 
myocardium is supplied by the untreated vessel/vessels with 
significant (.60%) diameter stenosis.19
Two cohorts of patients (levosimendan-mandatory and 
levosimendan-contraindicated) were defined based on the 
two distinct treatment strategies that were established and 
implemented at our clinic during this period. These two 
cohorts were compared in terms of clinical characteristics 
and 30-day mortality and at 1-year. The study was approved 
by the ethics committee.
Treatment strategy i
The first cohort (n = 46) consisted of patients enrolled between 
January 2004 and December 2005. During this period, levo-
simendan was used as the “first choice” agent to treat CS. 
According to the local regional guidelines, all patients with CS 
due to STEMI must be urgently transported to SU for primary 
PCI. In the catheterization laboratory (cath lab), introduction 
of an intraaortic balloon pump (IABP) and levosimendan 
were part of the mandatory treatment algorithm. These 
guidelines were based on our interpretation of the available 
data at the time, and were largely influenced by the results 
from the SHOCK,14 LIDO,20 RUSSLAN,21 CASINO,22 and 
OPTIME-HF23 clinical studies. Consequently, levosimendan 
was regarded as being superior to the traditional inotropes like 
dopamine, dobutamine, and milrinone. The patients could 
also receive combination therapies such as levosimendan 
plus noradrenalin or levosimendan plus dopamine or dobu-
tamine if monotherapy with levosimendan did not result in 
hemodynamic stability, although polypharmacy was generally 
discouraged. The choice of the additional catecholamine agent 
was left at the discretion of the attending physician. Treat-
ment with levosimendan could be commenced in the cath lab 
before, during, or after the revascularization procedure start-
ing with an IV bolus of 12 µg/kg followed by a continuous 
infusion of 0.1 µg/kg/min for 24 hours or 48 hours. An attempt 
to discontinue inotropic support with noradrenalin, dopamine, 
and dobutamine (if used with levosimendan) was recom-
mended as soon as the patient achieved hemodynamic stability 
for .12 hours. Stability was defined as systolic blood pressure 
.110 mmHg, mean arterial pressure (MAP) . 60 mmHg, 
cardiac index of 2.2 L/min/m2, good peripheral perfusion, and 
urine output .50 mL per hour. Levosimendan infusion was Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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allowed to continue for either 24 hours or 48 hours, even if 
hemodynamic stability was achieved. Cardiac output, cardiac 
index and mixed venous oxygen saturation were monitored 
continuously with pulmonary artery catheter.
Treatment strategy ii
After presentation of the data from the SURVIVE8 and 
REVIVE-II9 studies at the AHA meeting in 2005, we revised 
our guidelines. Based on the new data, levosimendan was 
excluded from the treatment algorithm due to concern about 
the increased incidence of hypotension and arrhythmias 
observed in these studies that might increase mortality in 
patients with CS. Consequently, none of the patients enrolled 
between December 2005 and December 2006 received levo-
simendan (n = 48). The new recommendation was to apply a 
restrictive approach regarding the use of all inotropic agents, 
ie, the routine use of inotropes was strongly discouraged. 
Inotropic support was recommended only if the reperfusion 
therapy, optimal hydration therapy and IABP support did not 
improve the patient’s hemodynamic status. The hemodynamic 
and clinical goals were systolic blood pressure .110 mmHg, 
MAP . 60 mmHg, cardiac index of 2.2 L/min/m2, good 
peripheral perfusion, and urine output .50 mL per hour. This 
approach is different from the previous strategy because all 
patients in the levosimendan-mandatory group received levo-
simendan early in the clinical course on a routine basis. The 
choice of appropriate agent (ie, dopamine, noradrenalin, dobu-
tamine, or milrinone) was left to the discretion of the attending 
physicians. Standard doses and up-titration schemes were 
used as recommended by the responsible   pharmacological 
companies. An attempt to discontinue inotropic support was 
recommended as soon as patient had achieved hemodynamic 
stability, defined as systolic blood pressure .110 mmHg and 
urine output .50 mL per hour.
statistics
Continuous variables are expressed as the means ± standard 
deviations and categorical variables as percentages. Com-
parisons between continuous variables were performed 
using Student’s t-test. Pearson’s Chi-square or Fisher’s exact 
tests were used to compare categorical variables. Normality 
of the variables was tested with the Kolmogorov-Smirnov 
test. Cox-regression with a forward stepwise model was 
used to adjust for the differences between the two cohorts. 
The following variables were included in the model: age, 
gender, hypertension, smoking, IABP, treatment with levo-
simendan, success of revascularization, and completeness 
of   revascularization. All statistical analyses were performed 
using SPSS® software (version 17.0.2, SPSS Inc., Chicago, 
IL, USA). Statistical significance was considered at P , 0.05 
(for two-tailed hypothesis).
Results
Patients
The cohorts were similar with respect to pre-treatment char-
acteristics and concomitant medications (Tables 1 and 2).
Treatments
The data are summarized in Tables 2 and 3. After the initial 
evaluation with coronary angiography, 92 patients (98%) 
Table 1 Patient characteristics i
Levosimendan mandatory  
n = 46
Levosimendan contraindicated 
n = 48
P-value
Age (mean ± sD) 65 ± 12.1 67 ± 10.8 0.39
Female, n (%) 11 (23.9) 14 (29.2) 0.56
Hypertension, n (%) 17 (37.0) 20 (41.7) 0.64
Diabetes, n (%) 10 (21.7) 14 (29.2) 0.41
Previous Mi, n (%) 9 (19.6) 8 (16.7) 0.71
Previous cABg, n (%) 0 (0.0) 2 (4.2) 0.16
Previous Pci, n (%) 2 (4.3) 4 (8.3) 0.43
insulin, n (%) 3 (6.5) 6 (12.5) 0.32
Anti-diabetic po, n (%) 5 (10.9) 2 (4.2) 0.22
Beta-blockade, n (%) 11 (23.9) 11 (22.9) 0.91
Ace, n (%) 9 (19.6) 5 (10.4) 0.21
ARB, n (%) 3 (6.5) 4 (8.3) 0.74
statin, n (%) 7 (15.2) 4 (8.3) 0.29
AsA, n (%) 13 (28.3) 9 (18.8) 0.28
Warfarin, n (%) 0 (0.0) 3 (6.3) 0.09
Abbreviations: Ace, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AsA, acetylsalicylic acid; cABg, coronary artery bypass graft; Mi, 
myocardial infarction; Pci, percutaneous coronary intervention; po, per oral.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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underwent acute PCI intervention and 2 patients (2%) (from 
the levosimendan-mandatory group) underwent acute coro-
nary bypass surgery (P = 0.24). The most frequently treated 
vessel was the left anterior descending artery (LAD) and right 
coronary artery (RCA) in both cohorts, respectively (Table 2). 
Complete revascularization was achieved in approximately half 
of all admitted patients and was similar in both groups (Table 2). 
The procedural success was generally high, and the procedure 
was deemed unsuccessful in only a few cases (Table 2).
The use of thrombolytic therapy prior to arrival in the 
cath lab was low (Table 3). All patients who underwent PCI 
revascularization were treated with a glycoprotein IIb/IIIa 
receptor (GP IIa/IIIb) inhibitor, which was started in the cath 
lab and continued in the intensive care unit (ICU). The length 
of stay in the ICU was similar between the groups. There was 
no difference in the incidence of new-onset atrial fibrillation 
or atrioventricular (AV) block (Table 3). Drug eluting stents 
were used only in a few patients. The use of inotropic therapy 
was almost halved (P , 0.001) in the second cohort, reflecting 
adherence to the change in the treatment guidelines (Table 3). 
The number of in-hospital cardiac arrests and resuscitation 
procedures was low, and was similar in both groups. A majority 
of patients were treated with bare metal stents (97.3% in the 
levosimendan mandatory group and 95.9% in the levosimendan 
contraindicated group, P = 0.58). Only a minority of patients 
were treated with drug-eluting stents (2.4% and 4.1%, P = 0.58 
in the levosimendan mandatory group and the levosimendan 
contraindicated group respectively). There was no difference in 
average stent length (18.4 mm and 18.9 mm, P = 0.66) as well as 
in stent diameter (3.4 mm and 3.5 mm, P = 0.79) in the levosim-
endan-mandatory group and the   levosimendan-contraindicated 
group respectively. There was no difference in the treatment 
with continuous positive airway pressure (CPAP) between the 
groups (40% vs 41%, P = 0.9).
Mortality
The patient follow-up was 100%. The majority of deaths 
occurred within 30 days post-MI, and included 15 (32.6%) 
patients in the first cohort and 17 (35.4%) in the second cohort 
(Figure 1). After 30 days, five additional patients died in the 
Table 2 Angiography and revascularization
Levosimendan mandatory  
n = 46 
Levosimendan contraindicated  
n = 48 
P-value
Angiography findings
One-vessel disease, n (%) 11 (23.9) 9 (18.8) 0.53
Multi-vessel disease, n (%) 26 (56.5) 32 (66.7) 0.44
Left main disease, n (%) 9 (19.6) 7 (14.5) 0.51
Number of treated segments
LM, n (%) 2 (1.9) 8 (6.6) 0.11
LAD, n (%) 48 (45.3) 42 (34.7) 0.13
Lcx, n (%) 24 (22.6) 29 (23.9) 0.88
RcA, n (%) 32 (30.2) 42 (34.7) 0.48
saphenous graft, n (%) 0 (0.0) 1 (0.1) 0.31
compl. revasc., n (%) 23 (50.0) 19 (39.6) 0.31
success. proc., n (%) 43 (93.5) 41 (85.4) 0.20
Abbreviations: Compl. revasc., completeness of revascularization; LAD, left anterior descending artery; LCx, left circumflex artery; LM, left main; RCA, right coronary 
artery; success. proc., successful procedure.
Table 3 Patient characteristics ii
Levosimendan mandatory  
n = 46 
Levosimendan contraindicated  
n = 48 
P-value
iABP, n (%)  34 (73.9) 39 (81.3) 0.46
Resuscitation, n (%) 1 (2.2) 1 (2.1) 0.97
inotropy, n (%) 46 (100) 26 (54.2) 0.01
Thrombolytics, n (%) 2 (4.3) 1 (2.1) 0.61
gP iib/iiia, n (%) 44 (0.96) 48 (100) 0.49
icU days, (median ± iQR) 7 (3–15) 7 (3–14) 0.54
AV-block, n (%) 3 (6.5) 4 (8.3) 0.72
Atrial fib., n (%) 8 (17.4) 8 (16.7) 0.93
Abbreviations: Atrial fib., atrial fibrillation; AV-block, AV block II or III; GP IIb/IIIa, glycoprotein IIb/IIIa receptor inhibitors; IABP, intraaortic balloon pump counterpulsation; 
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levosimendan-mandatory group while no deaths occurred in 
the levosimendan-contraindicated group. There was no dif-
ference in the adjusted 30-day mortality (hazard ratio [HR] 
0.97; confidence interval [CI] 0.53–1.78; P = 0.93) and 1-year 
mortality (HR 1.05; CI 0.57–1.92; P = 0.87) between the 
groups (Figure 1). In the Cox proportional hazard regression, 
age, procedural success, and completeness of revasculariza-
tion were independent predictors of mortality (Table 4).
Discussion
Cardiogenic shock is a serious complication of acute myocar-
dial infarction. Prompt and successful revascularization is the 
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Figure 1 Kaplan-Meier curve for 1-year mortality. There was no difference in the unadjusted or adjusted mortality rates between the two cohorts at 30 days and at 1 year. 
The majority of patients died within 30 days post-myocardial infarction.
Table 4 cox proportional-hazard regression
HR* CI P-value
Age 1.05 1.01–1.08 0.01
compl. revasc 0.49 0.24–0.98 0.04
success. proc. 0.38 0.15–0.98 0.04
Levosimendan 1.3 0.66–2.23 0.52
*Risk of death according to treatment assignment and prognostic variables.
Abbreviations:  CI,  95%  confidence  interval;  Compl.  revasc.,  completeness  of 
revascularization; HR, hazard ratio; success. proc., successful procedure.
only documented treatment strategy that reduces mortality.14 
No firm scientific evidence has been presented to support the 
use of inotropic agents in the treatment of CS. In this study, 
we compared two treatment strategies from every-day clini-
cal practice at a large university clinic. The most important 
result is that the use of levosimendan in CS has neutral effects 
on short-term and long-term mortality under the conditions 
described in the study.
Levosimendan is an inotropic agent approved in some 
countries for a treatment of AHF.24 It has been proposed that 
the positive inotropic effect of this substance is primarily 
mediated through calcium sensitization of troponin-C, 
and that this action does not increase myocardial oxygen 
consumption for a given inotropic effect when compared with 
traditional inotropic agents such as β-adrenergic receptor 
agonists (eg, dopamine, dobutamine) and phosphodiesterase 
(PDE) inhibitors (eg, milrinone).25 Levosimendan was intro-
duced on the market during an era of increased awareness 
regarding the negative effects of inotropic agents on mortality 
in chronic heart failure (CHF) patients. This paradigm-shift 
was the result of compelling evidence from large randomized Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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clinical trials   showing that neurohormonal blockade (and 
therefore   negative inotropy) improves the biology of the 
failing heart and prolongs life.26,27 Consequently, the advent 
of a pharmacological agent with the above-mentioned phar-
macodynamic profile was very attractive, and levosimendan 
was enthusiastically accepted by many clinicians. However, 
this initial enthusiasm has been dampened considerably 
by accumulating evidence from experimental and clini-
cal studies. Disappointingly, levosimendan acts much like 
traditional inotropic agents in terms of PDE inhibition,28,29 
increased intracellular calcium concentration,30 and increased 
oxygen demands.31 Levosimendan has been reported to have 
cardioprotective effects25,32–35 in vitro and in animal models, 
although the significance of these ancillary pharmacody-
namic properties for clinical end-points has not been clearly 
demonstrated. Indeed, the similarity between the traditional 
inotropes and levosimendan has been unambiguously demon-
strated in two large clinical trials: SURVIVE8 and REVIVE 
II.9 Interestingly, the latter study has not been published in its 
entirety, although the trial data was first presented in 2005. 
Only two studies with levosimendan in CS have reported 
survival rates.36,37 Our findings reinforce data from a small 
randomized study comparing levosimendan with dobutamine 
on long-term survival. In this study, levosimendan and 
dobutamine had similar effects on survival at one-year.37 
The absence of a meaningful clinical benefit (ie, morbidity, 
mortality) and high cost of levosimendan (eg, 10 times the 
cost of dopamine), in our opinion does not justify routine use 
of this agent for the “on-label” indication in AHF and even 
less so for the “off-label” indications, such as CS.
The strength of our study is the relatively large number of 
patients included, and that it was conducted at a large clinic 
with a well-organized and consistent prehospitalization and 
hospital care system. This ensures that a uniform approach 
was used for all patients, thus minimizing the effects of ran-
dom variables caused by the absence of randomization.
Limitations
This was an observational study, and as such the results 
should be viewed primarily as hypothesis-building. Although 
we compensated for the differences in patient characteristics 
using standard statistical modeling, the inability to adjust for 
unknown confounders is inherent to observational   studies. 
The use of levosimendan was not associated with any appar-
ent adverse effects. However, levosimendan was part of 
the treatment concept together with revascularization and 
IABP. We cannot, therefore, extend our conclusions to the 
CS patients who were treated differently. It is possible that 
the use of IABP might have masked some of the adverse 
effects of levosimendan, such as hypotension, arrhythmias, 
and increased mortality.
Conclusion
Levosimendan neither decreases nor increases mortality in 
patients with CS. There is a compelling need to define the 
role of inotropic agents and other therapeutic interventions 
in the treatment of CS. This goal can only be achieved by 
well designed and conducted randomized trials.
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